HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1

Rhea-AI Summary

HeartSciences (Nasdaq: HSCS) announced the commercial launch of MyoVista Insights version 1.1 on December 11, 2025, a cloud-native ECG reporting and management platform designed to host AI ECG algorithm models from multiple partners.

Version 1.1 emphasizes usability, expanded interoperability across ECG devices and file formats, enhanced waveform tools, streamlined study organization, and workflow efficiency aimed at improving clinical interpretation and reducing operational costs. The company reported early adopter validation and ongoing commercial discussions with leading healthcare institutions since the platform's May 2025 launch.

Positive

• Commercial release of MyoVista Insights 1.1 on Dec 11, 2025
• Cloud-native platform designed to host AI ECG models from multiple partners
• Expanded interoperability across multiple ECG devices and file formats

Negative

• None.

Key Figures

Cash balance $2.8 million Q1 fiscal 2026 as of July 31, 2025

Shareholders' equity $3.1 million Q1 fiscal 2026 as of July 31, 2025

Cash balance $1.1 million Fiscal 2025 as of April 30, 2025

Reg A+ proceeds $3.1 million Capital raised after fiscal 2025

CMS reimbursement $128 per test AI-ECG algorithm reimbursement rate

Granted patents 44 patents Worldwide patent portfolio for AI-ECG technology

S-8 registered shares 209,857 shares Registered under 2023 Equity Incentive Plan

Reoffer prospectus shares 252,561 shares Shares that may be resold by affiliates under S-8

Market Reality Check

$2.62 Last Close

Volume Volume 16,235 vs 20-day average 45,527 (relative volume 0.36), indicating muted trading activity pre-announcement. low

Technical Shares at $2.62 are below the 200-day MA of $3.38 and 59.51% under the 52-week high.

Peers on Argus 2 Up

Within medical devices peers, moves are mixed: BMRA up 2.46%, PAVM up 0.28%, RSLS up 29.8%, SSKN down 5%, DHAI flat. Momentum scanner shows BMRA and AMIX up around 4%, suggesting some stock-specific strength but not a broad sector move tied to this software update.

Common Catalyst One peer, BMRA, had regulatory-related news on test portfolio authorization, indicating company-specific catalysts rather than a unified sector driver.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Sep 11	Earnings and update	Neutral	-10.0%	Q1 2026 results with tech progress but no meaningful revenue yet.
Aug 15	Investor outreach	Neutral	-3.4%	Announcement of investor webinar and conference participation.
Jul 24	Full-year earnings	Positive	+0.3%	Fiscal 2025 update with CMS reimbursement and AI-ECG milestones.

Pattern Detected

Recent HSCS news, including earnings and investor events, has often been followed by negative or muted price reactions, even when operational progress was highlighted.

Recent Company History

Over recent months, HeartSciences reported fiscal 2025 and Q1 fiscal 2026 results, emphasizing progress in its AI-powered ECG strategy. The company launched the MyoVista Insights cloud-native platform in May 2025 and secured CMS reimbursement at $128 per test, FDA Breakthrough Device designation, and a portfolio of 44 granted patents. Despite these milestones, Q1 2026 featured no meaningful revenue, and capital needs were addressed via Reg A+ offerings and debt-to-equity conversions. The new version 1.1 release extends this focus on building out the ECG software platform.

Market Pulse Summary

This announcement highlights a major usability and workflow upgrade to the MyoVista Insights ECG platform, with version 1.1 aimed at better clinical interpretation, interoperability, and efficiency. It extends a strategy that has already delivered CMS reimbursement at $128 per test, FDA Breakthrough Device designation, and a portfolio of 44 patents. Investors may focus on forthcoming customer deployment announcements, revenue ramp from AI-ECG services, and ongoing regulatory and financing developments seen in recent earnings reports and SEC filings.

Key Terms

ecg medical

"Designed to provide best usability of any ECG system"

An ECG (electrocardiogram) records the heart’s electrical activity through small sensors on the skin and produces a waveform that shows heart rate, rhythm and signs of stress or damage—think of it as a seismograph for the heart’s electrical signals. Investors care because ECGs are central to diagnosing and monitoring cardiac safety in clinical trials, required for regulatory approval of many drugs and devices, and drive demand for related medical equipment and services.

artificial intelligence technical

"through the integration of artificial intelligence (“AI”)"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

AI-generated analysis. Not financial advice.

Version 1.1 Designed to Provide Best Usability of any ECG System

Southlake, TX, Dec. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced the commercial release of MyoVista Insights™ version 1.1, a major update that is built to provide the most usable ECG system and enhances clinical interpretation capabilities, improves workflow efficiency, and expands interoperability across a broad range of ECG devices.

Andrew Simpson, CEO of HeartSciences said, “MyoVista Insights is a state-of-the-art ECG reporting and management platform that delivers substantial clinical, operational, and data-security benefits for healthcare systems, since its launch in May 2025, we’ve received strong validation from early adopters and are engaged in commercial discussions with several leading healthcare institutions. We look forward to announcing key customer deployments in the near term.”

MyoVista Insights is a cloud native, next generation ECG management system designed to host AI ECG algorithm models from multiple partners, improve workflow efficiency, streamline data management, and provide clinicians with greater flexibility across multiple ECG devices and file formats. It is being developed as a vendor and device agnostic platform that enhances clinical decision making, streamlines ECG workflows, and helps reduce operational costs for healthcare providers.

MyoVista Insights 1.1 delivers a more intuitive, efficient platform for cardiac care, helping clinicians turn complex ECG data into actionable insights. By streamlining study organization, enhancing waveform tools, and simplifying workflows, the platform allows care teams to focus on what matters most—interpreting results quickly, making informed decisions, and supporting better patient outcomes. These updates reinforce HeartSciences commitment to enabling timely, precise, and patient-centered cardiac care.

About HeartSciences
HeartSciences is a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”). Its MyoVista Insights platform is designed to provide device agnostic next-generation ECG system and is MyoVista wavECG device Is designed to provide its on device solutions,

For more information, please visit: https://www.heartsciences.com. X: @HeartSciences

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 24, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2025 filed with the SEC on September 11, 2025 and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Investor Relations:
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us

Media Contact:
HeartSciences
Gene Gephart
+1 682 244 2578 Ext. 2024
info@heartsciences.com

FAQ

What is MyoVista Insights version 1.1 that HeartSciences (HSCS) launched on December 11, 2025?

MyoVista Insights 1.1 is a cloud-native ECG reporting and management platform that hosts AI ECG algorithm models, improves workflow efficiency, and expands device interoperability.

How does MyoVista Insights 1.1 improve ECG interoperability for HSCS customers?

Version 1.1 expands support for a broad range of ECG devices and file formats, enabling vendor-agnostic data exchange and streamlined study organization.

What clinical and operational benefits does HSCS say MyoVista Insights 1.1 delivers?

The company cites enhanced clinical interpretation, improved waveform tools, simplified workflows, and potential reductions in operational costs for care teams.

When did HeartSciences first launch MyoVista Insights and what progress has it reported?

The platform launched in May 2025, and HeartSciences reports strong validation from early adopters and ongoing commercial discussions with healthcare institutions.

Will MyoVista Insights 1.1 support third-party AI ECG algorithms for HSCS users?

Yes. The platform is designed to host AI ECG algorithm models from multiple partners to support clinical decision making.

Where can investors find details about HeartSciences' commercial deployments for HSCS products?

HeartSciences said it is engaged in commercial discussions and expects to announce key customer deployments in the near term.